Biocon Ltd surged 9.8% on Monday after the drug maker announced that it has received an emergency use authorisation (EUA) for its monoclonal antibody Itoliuzumab from the Drug Controller General of India (DCGI) to treat cytokine storms - one of the leading causes of death among patients with severe covid-19.At 1105 am, shares were at ₹416.55, up 0.5% from its previous close, while the benchmark Sensex was up nearly 1% at 36,957.18.On Saturday, in a press release to the stock exchanges, Biocon said its subsidiary Biocon Biologics has received DCGI approval to market Itolizumab (ALZUMAb) Injection 25mg/5mL.Itolizumab is the first novel biologic therapy to be approved for treating patients with moderate to severe covid-19.The approval was.